XML 55 R45.htm IDEA: XBRL DOCUMENT
v3.22.2

Kolltan Acquisition (Details) - USD ($) |  |  | 6 Months Ended
--- | --- | --- | ---
Jun. 20, 2022 | Nov. 29, 2016 | Jun. 30, 2022
Kolltan Acquisition |  |  |
Execution of the settlement agreement | $ 15,000,000 |  |
Litigation Settlement, Expense |  |  | $ 15,000,000
European medicines agency |  |  |
Kolltan Acquisition |  |  |
Business contingent amount payable | 52,500,000 |  |
Clinical Trail [Member] |  |  |
Kolltan Acquisition |  |  |
Execution of the settlement agreement | 15,000,000 |  |
Litigation Settlement, Expense |  |  | $ 15,000,000.0
Contractual credit merger agreement | 2,500,000 |  |
Specified development, regulatory approvals or sales-based milestones |  |  |
Kolltan Acquisition |  |  |
Business contingent amount payable | $ 172,500,000 |  |
Kolltan |  |  |
Kolltan Acquisition |  |  |
Shares issued as part of consideration (in shares) |  | 1,217,200 |
Kolltan | Specified development, regulatory approvals or sales-based milestones |  |  |
Kolltan Acquisition |  |  |
Potential milestone payments |  | $ 172,500,000 |

X
- Definition Represents the Business Combination Contingent Consideration Contractual Credit In Merger Agreement. + References No definition available. + Details
Name: | cldx_BusinessCombinationContingentConsiderationContractualCreditInMergerAgreement
Namespace Prefix: | cldx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Represents the Business combination contingent consideration settlement agreement amount paid. + References No definition available. + Details
Name: | cldx_BusinessCombinationContingentConsiderationSettlementAgreementAmountPaid
Namespace Prefix: | cldx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Represents the Business Combination Contingent Consideration Settlement Agreement Amount Payable. + References No definition available. + Details
Name: | cldx_BusinessCombinationContingentConsiderationSettlementAgreementAmountPayable
Namespace Prefix: | cldx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Number of shares of equity interests issued or issuable to acquire entity. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -SubTopic 30 -Section 50 -Paragraph 1 -Subparagraph (b)(4) -URI https://asc.fasb.org/extlink&oid=126975305&loc=d3e6927-128479 + Details
Name: | us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued
Namespace Prefix: | us-gaap_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | duration

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_BusinessAcquisitionLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition For contingent consideration arrangements recognized in connection with a business combination, this element represents an estimate of the high-end of the potential range (undiscounted) of the consideration which may be paid. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -SubTopic 30 -Section 50 -Paragraph 1 -Subparagraph (c)(3) -URI https://asc.fasb.org/extlink&oid=126975305&loc=d3e6927-128479 + Details
Name: | us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Amount of litigation expense, including but not limited to legal, forensic, accounting, and investigative fees. + References No definition available. + Details
Name: | us-gaap_LitigationSettlementExpense
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Details
Name: | us-gaap_UnderlyingAssetClassAxis=cldx_EuropeanMedicinesAgencyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FinancialInstrumentAxis=cldx_ClinicalTrailMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ContingentConsiderationByTypeAxis=cldx_ContingentMilestoneMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_BusinessAcquisitionAxis=cldx_KolltanPharmaceuticalsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |